Global Blood Therapeutics (Global Blood Therapeutics) GF Value : $80.88 (As of May. 09, 2024)

View and export this data going back to 2015. Start your Free Trial

What is Global Blood Therapeutics GF Value?

The GF Value represents the current intrinsic value of a stock derived from our exclusive method. The GF Value Line on our summary page gives an overview of the fair value that the stock should be traded at. It is calculated based on three factors:

Historical multiples (PE Ratio, PS Ratio, PB Ratio and Price-to-Free-Cash-Flow) that the stock has traded at.
GuruFocus adjustment factor based on the company’s past returns and growth.
Future estimates of the business performance.

We believe the GF Value Line is the fair value that the stock should be traded at. The stock price will most likely fluctuate around the GF Value Line. If the stock price is significantly above the GF Value Line, it is overvalued and its future return is likely to be poor. On the other hand, if it is significantly below the GF Value Line, its future return will likely be higher.

Please note, "Possible Value Trap, Think Twice" is for the companies that look very undervalued, but either in the long term trend of business decline, or in financial distress.

As of today (2024-05-09), Global Blood Therapeutics's share price is $68.49. Global Blood Therapeutics's GF Value is $80.88. Therefore, Global Blood Therapeutics's Price-to-GF-Value for today is 0.85.

Based on the relationship between the current stock price and the GF Value, GuruFocus believes Global Blood Therapeutics is Data Out of Date, Use Caution.

Global Blood Therapeutics (NAS:GBT) GF Value Explanation

Based on the relationship between the current stock price and the GF Value, GuruFocus provides the following 6 evaluations:

Posssible Evaluations	All-in-One Screener Examples (2)
Possible Value Trap, Think Twice (1)	Predictable Companies that possibly be Value Traps
Significantly Overvalued	Predictable Companies which are Significantly Overvalued
Modestly Overvalued	Predictable Companies which are Modestly Overvalued
Fairly Valued	Predictable High Quality Companies which are Fairly Valued
Modestly Undervalued (3)	Predictable High Quality Companies which are Modestly Undervalued
Significantly Undervalued (3)	Predictable High Quality Companies which are Significantly Undervalued

(1) "Possible Value Trap, Think Twice" is for the companies that look very undervalued, but either in the long term trend of business decline, or in financial distress.

(2) These are some simple examples. You can access our GF Valuation filter under All-in-One Screener’s Fundamental tab, and Price-to-GF-Value filter under Valuation Ratio tab and set your own criteria.

(3) There is only a sufficient margin of safety when the stock is undervalued.

Global Blood Therapeutics's Price-to-GF-Value for today is calculated as

Price-to-GF-Value	=	Share Price	/	GF Value
	=	68.49	/	80.88
	=	0.85

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Global Blood Therapeutics GF Value Related Terms

Thank you for viewing the detailed overview of Global Blood Therapeutics's GF Value provided by GuruFocus.com. Please click on the following links to see related term pages.

Global Blood Therapeutics (Global Blood Therapeutics) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Global Blood Therapeutics Inc (NAS:GBT) » Definitions » GF Value

Comparable Companies

Traded in Other Exchanges

N/A

Address

181 Oyster Point Boulevard, South San Francisco, CA, USA, 94080

Website

https://www.gbt.com

Global Blood Therapeutics Inc operates in the healthcare sector of the United States. It discovers and develops novel therapeutics to address blood-based disorders. GBT440, its lead drug candidate targets the underlying mechanism of red blood cell (RBC) sickling, which provides the potential to treat sickle cell disease. GBT440. an oral, once-daily therapy arrests abnormal hemoglobin polymerization, the underlying mechanism of RBC sickling. In addition, the company is engaged in other research and development activities targeted at hereditary angioedema and owns exclusively licensed rights to its portfolio of product candidates in the United States, Europe, and other major markets.

Executives

Jeffrey S Farrow	officer: Chief Financial Officer	TWO CORPORATE DRIVE, SOUTH SAN FRANCISCO CA 94080
Nazila Habibizad	officer: See Remarks	C/O GLOBAL BLOOD THERAPEUTICS, INC. 181 OYSTER POINT BLVD SOUTH SAN FRANCISCO CA 94080
Dawn Svoronos	director	C/O MEDIVATION, INC., 525 MARKET ST., 36TH FLOOR, SAN FRANCISCO CA 94105
Philip A. Pizzo	director	ONE COMMERCE STREET, SUITE 2550, MEMPHIS TN 38103
Scott W Morrison	director	C/O GLOBAL BLOOD THERAPEUTICS, INC., 400 EAST JAMIE COURT SUITE 101, SOUTH SAN FRANCISCO CA 94080
Carrie Krehlik	officer: Chief Human Resources Officer	6015 COLTON BLVD, OAKLAND CA 94611
Eric Fink	officer: Chief Human Resources Officer	C/O GLOBAL BLOOD THERAPEUTICS, INC. 171 OYSTER POINT BLVD., SUITE 300 SOUTH SAN FRANCISCO CA 94080
Kim Smith-whitley	officer: See Remarks	C/O GLOBAL BLOOD THERAPEUTICS, INC. 181 OYSTER POINT BLVD. SOUTH SAN FRANCISCO CA 94080
Alexis A. Thompson	director	C/O GLOBAL BLOOD THERAPEUTICS, INC. 181 OYSTER POINT BLVD. SOUTH SAN FRANCISCO CA 94080
Brian Edwin Cathers	officer: Chief Scientific Officer	C/O GLOBAL BLOOD THERAPEUTICS, INC. 171 OYSTER POINT BLVD., SUITE 300 SOUTH SAN FRANCISCO CA 94080
Lesley Ann Calhoun	officer: See Remarks	C/O GLOBAL BLOOD THERAPEUTICS, INC., 171 OYSTER POINT BOULEVARD, SUITE 300, SOUTH SAN FRANCISCO CA 94080
Mark L Perry	director	176 WEST BLITHEDALE AVE, MILL VALLEY CA 94941
Ted W Love	director, officer: See Remarks	C/O GLOBAL BLOOD THERAPEUTICS, INC., 400 EAST JAMIE COURT, SUITE 101, SOUTH SAN FRANCISCO CA 94080
Tricia Borga Suvari	officer: Chief Legal Officer	3172 PORTER DRIVE PALO ALTO CA 94034
Brown Willie L. Jr.	director	C/O GLOBAL BLOOD THERAPEUTICS, INC. 400 EAST JAMIE COURT, SUITE 101 SOUTH SAN FRANCISCO CA 94080